Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Bio-Techne Co. (NASDAQ:TECH – Free Report) by 1.8% in the third quarter, Holdings Channel.com reports. The firm owned 16,347 shares of the biotechnology company’s stock after acquiring an additional 289 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Bio-Techne were worth $1,307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently bought and sold shares of the company. Mather Group LLC. bought a new position in shares of Bio-Techne during the 1st quarter worth about $38,000. AdvisorNet Financial Inc lifted its holdings in shares of Bio-Techne by 680.0% during the 1st quarter. AdvisorNet Financial Inc now owns 3,307 shares of the biotechnology company’s stock worth $233,000 after acquiring an additional 2,883 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Bio-Techne by 11.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 27,978 shares of the biotechnology company’s stock worth $1,969,000 after acquiring an additional 2,913 shares during the period. Azzad Asset Management Inc. ADV lifted its holdings in shares of Bio-Techne by 2.3% during the 1st quarter. Azzad Asset Management Inc. ADV now owns 44,570 shares of the biotechnology company’s stock worth $3,137,000 after acquiring an additional 1,023 shares during the period. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Bio-Techne by 25.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 18,440 shares of the biotechnology company’s stock worth $1,298,000 after acquiring an additional 3,775 shares during the period. 98.95% of the stock is owned by institutional investors.
Bio-Techne Trading Down 0.6 %
TECH opened at $69.95 on Wednesday. The company has a current ratio of 3.87, a quick ratio of 2.75 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $11.10 billion, a PE ratio of 67.26, a PEG ratio of 5.15 and a beta of 1.27. Bio-Techne Co. has a 1-year low of $51.79 and a 1-year high of $85.57. The firm has a 50-day moving average price of $74.02 and a two-hundred day moving average price of $74.50.
Bio-Techne Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, August 30th. Shareholders of record on Monday, August 19th were given a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.46%. The ex-dividend date was Monday, August 19th. Bio-Techne’s payout ratio is presently 30.77%.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on TECH. Benchmark reaffirmed a “buy” rating and set a $95.00 price objective on shares of Bio-Techne in a report on Tuesday, August 13th. Royal Bank of Canada reduced their price objective on shares of Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating for the company in a report on Thursday, August 8th. Finally, Robert W. Baird increased their target price on shares of Bio-Techne from $81.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $80.60.
View Our Latest Research Report on Bio-Techne
Bio-Techne Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Recommended Stories
- Five stocks we like better than Bio-Techne
- 3 REITs to Buy and Hold for the Long Term
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What to Know About Investing in Penny Stocks
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Most active stocks: Dollar volume vs share volume
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Co. (NASDAQ:TECH – Free Report).
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.